Literature DB >> 68279

Clinical spectrum of gonococcal infection in women.

W M McCormack, R J Stumacher, K Johnson, A Donner.   

Abstract

The medical records of 278 women infected with Neisseria gonorrhoeae during a 6-month period were reviewed. These represented 75% of the infections in women at Boston City Hospital during this time. Women who presented to the venereal-disease clinic because they had had contact with an infected man and women who were found to be infected during routine examinations in the obstetrics-and-gynaecology clinic were usually free of symptoms or had non-specific symptoms such as vaginal discharge. However, these women accounted for only 108 (39%) of the 278 infections. Most of the infections were in women who presented to the emergency-care areas of the hospital with symptomatic gonococcal infections. At least 86 (31%) of the 278 infections were in women who had pelvic inflammatory disease. These data indicate that the clinical spectrum of gonococcal infection varies according to where the patients are seen and that the widely held concept that most gonococcal infections in women are asymptomatic may be erroneous.

Entities:  

Mesh:

Year:  1977        PMID: 68279     DOI: 10.1016/s0140-6736(77)92720-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  16 in total

1.  Conserved regions of gonococcal TbpB are critical for surface exposure and transferrin iron utilization.

Authors:  Karen L Ostberg; Amanda J DeRocco; Shreni D Mistry; Mary Kathryne Dickinson; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

2.  The iron-repressed, AraC-like regulator MpeR activates expression of fetA in Neisseria gonorrhoeae.

Authors:  Aimee Hollander; Alexandra Dubon Mercante; William M Shafer; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2011-09-26       Impact factor: 3.441

3.  Vaccine against gonorrhoea.

Authors:  A A Glynn; C Ison
Journal:  Br Med J       Date:  1977-10-29

4.  Asymptomatic non-ulcerative genital tract infections in a rural Ugandan population.

Authors:  L A Paxton; N Sewankambo; R Gray; D Serwadda; D McNairn; C Li; M J Wawer
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

5.  Anaerobic metabolism occurs in the substratum of gonococcal biofilms and may be sustained in part by nitric oxide.

Authors:  Megan L Falsetta; Alastair G McEwan; Michael P Jennings; Michael A Apicella
Journal:  Infect Immun       Date:  2010-03-15       Impact factor: 3.441

6.  Growth of Neisseria gonorrhoeae in the female mouse genital tract does not require the gonococcal transferrin or hemoglobin receptors and may be enhanced by commensal lactobacilli.

Authors:  Ann E Jerse; Emily T Crow; Amy N Bordner; Ishrat Rahman; Cynthia Nau Cornelissen; Thomas R Moench; Karim Mehrazar
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

7.  InTray GC medium versus modified Thayer-Martin agar plates for diagnosis of gonorrhea from endocervical specimens.

Authors:  A Beverly; J R Bailey-Griffin; J R Schwebke
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

8.  The incidence and correlates of symptomatic and asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae infections in selected populations in five countries.

Authors:  Roger Detels; Annette M Green; Jeffrey D Klausner; David Katzenstein; Charlotte Gaydos; H Hunter Handsfield; Willo Pequegnat; Kenneth Mayer; Tyler D Hartwell; Thomas C Quinn
Journal:  Sex Transm Dis       Date:  2011-06       Impact factor: 2.830

9.  Antibodies to gonococcal pili in women with asymptomatic gonorrhoea. Diagnostic value of the ELISA for testing women attending an STD clinic.

Authors:  A P Oranje; C O Iserief; A de Roo; E Stolz; M F Michel
Journal:  Br J Vener Dis       Date:  1983-04

10.  Passive hemagglutination test for detection of antibody to gonococcal ribosomal antigen in sera from patients with asymptomatic gonorrhea.

Authors:  E Kita; S Kashiba
Journal:  J Clin Microbiol       Date:  1982-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.